Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery ...

Venetia Zachariou, PhD, Edward Avedisian Professor and chair of pharmacology, physiology & biophysics at Boston University Chobanian & Avedisian School of Medicine, has received a Distinguished ...

Dogwood Therapeutics, Inc. has announced the dosing ... which studies Halneuron® as a treatment for chemotherapy-induced neuropathic pain. Halneuron® is designed to target the NaV 1.7 sodium ...

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood” or the "Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute ...

THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain ...